Research programme: diabetes mellitus therapeutic - Yuhan CorporationAlternative Names: YH 25348; YH 25723; YH 25724; YH-Bio1; YHbio1
Latest Information Update: 26 Sep 2016
At a glance
- Originator Yuhan
- Class Recombinant proteins
- Mechanism of Action Fibroblast growth factor 21 agonists; Glucagon like peptide 1 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetes mellitus